These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 24719940)

  • 1. Pharmacokinetics of carbon nanoparticle-paclitaxel suspension for use in intraperitoneal chemotherapy.
    Cai Y; Zhang X
    Hepatogastroenterology; 2013; 60(128):1998-2003. PubMed ID: 24719940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Preparation of carbon nanoparticle paclitaxel suspension and pharmacokinetic study of intraperitoneal chemotherapy].
    Cai YK; Zhang XY
    Zhonghua Wei Chang Wai Ke Za Zhi; 2011 Dec; 14(12):973-6. PubMed ID: 22205462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and tissue distribution of intraperitoneal paclitaxel with different carrier solutions.
    Mohamed F; Marchettini P; Stuart OA; Sugarbaker PH
    Cancer Chemother Pharmacol; 2003 Nov; 52(5):405-10. PubMed ID: 12879282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different tissue distribution of paclitaxel with intravenous and intraperitoneal administration.
    Soma D; Kitayama J; Ishigami H; Kaisaki S; Nagawa H
    J Surg Res; 2009 Jul; 155(1):142-6. PubMed ID: 19328496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paclitaxel nanoparticle inhibits growth of ovarian cancer xenografts and enhances lymphatic targeting.
    Lu H; Li B; Kang Y; Jiang W; Huang Q; Chen Q; Li L; Xu C
    Cancer Chemother Pharmacol; 2007 Feb; 59(2):175-81. PubMed ID: 16718469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Docetaxel: pharmacokinetics and tissue levels after intraperitoneal and intravenous administration in a rat model.
    Marchettini P; Stuart OA; Mohamed F; Yoo D; Sugarbaker PH
    Cancer Chemother Pharmacol; 2002 Jun; 49(6):499-503. PubMed ID: 12107555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surfactants influence the distribution of taxanes in peritoneal dissemination tumor-bearing rats.
    Kamijo Y; Ito C; Nomura M; Sai Y; Miyamoto K
    Cancer Lett; 2010 Jan; 287(2):182-6. PubMed ID: 19608331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disposition kinetics of taxanes after intraperitoneal administration in rats and influence of surfactant vehicles.
    Yokogawa K; Jin M; Furui N; Yamazaki M; Yoshihara H; Nomura M; Furukawa H; Ishizaki J; Fushida S; Miwa K; Miyamoto K
    J Pharm Pharmacol; 2004 May; 56(5):629-34. PubMed ID: 15142340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of paclitaxel-containing liposomes in rats.
    Fetterly GJ; Straubinger RM
    AAPS PharmSci; 2003 Nov; 5(4):E32. PubMed ID: 15198520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Translymphatic chemotherapy by intrapleural placement of gelatin sponge containing biodegradable Paclitaxel colloids controls lymphatic metastasis in lung cancer.
    Liu J; Meisner D; Kwong E; Wu XY; Johnston MR
    Cancer Res; 2009 Feb; 69(3):1174-81. PubMed ID: 19176391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded nanosponges.
    Torne SJ; Ansari KA; Vavia PR; Trotta F; Cavalli R
    Drug Deliv; 2010 Aug; 17(6):419-25. PubMed ID: 20429848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of genistein on the pharmacokinetics of paclitaxel administered orally or intravenously in rats.
    Li X; Choi JS
    Int J Pharm; 2007 Jun; 337(1-2):188-93. PubMed ID: 17267149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and characterization of a novel polydepsipeptide contained tri-block copolymer (mPEG-PLLA-PMMD) as self-assembly micelle delivery system for paclitaxel.
    Zhao Y; Li J; Yu H; Wang G; Liu W
    Int J Pharm; 2012 Jul; 430(1-2):282-91. PubMed ID: 22484705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Altered pharmacokinetics of paclitaxel by the concomitant use of morin in rats.
    Choi BC; Choi JS; Han HK
    Int J Pharm; 2006 Oct; 323(1-2):81-5. PubMed ID: 16806758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma and tissue disposition of paclitaxel (taxol) after intraperitoneal administration in mice.
    Innocenti F; Danesi R; Di Paolo A; Agen C; Nardini D; Bocci G; Del Tacca M
    Drug Metab Dispos; 1995 Jul; 23(7):713-7. PubMed ID: 7587959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paclitaxel loaded PEG(5000)-DSPE micelles as pulmonary delivery platform: formulation characterization, tissue distribution, plasma pharmacokinetics, and toxicological evaluation.
    Gill KK; Nazzal S; Kaddoumi A
    Eur J Pharm Biopharm; 2011 Oct; 79(2):276-84. PubMed ID: 21575719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The inhibitory effect of paclitaxel nanoparticles on ovarian cancer xenografts and lymphatic targeting].
    Lu HX; Xu CJ; Li B; Kang Y; Huang Q; Li LM; Chen QH
    Beijing Da Xue Xue Bao Yi Xue Ban; 2006 Oct; 38(5):483-6. PubMed ID: 17068619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Copolymer micelles and nanospheres with different in vitro stability demonstrate similar paclitaxel pharmacokinetics.
    Letchford K; Burt HM
    Mol Pharm; 2012 Feb; 9(2):248-60. PubMed ID: 22204437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients.
    Bulitta JB; Zhao P; Arnold RD; Kessler DR; Daifuku R; Pratt J; Luciano G; Hanauske AR; Gelderblom H; Awada A; Jusko WJ
    Cancer Chemother Pharmacol; 2009 May; 63(6):1049-63. PubMed ID: 18791718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct comparison of two albumin-based paclitaxel-loaded nanoparticle formulations: is the crosslinked version more advantageous?
    Li C; Li Y; Gao Y; Wei N; Zhao X; Wang C; Li Y; Xiu X; Cui J
    Int J Pharm; 2014 Jul; 468(1-2):15-25. PubMed ID: 24709221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.